.. Validité-externe, 74 3.1. Conclusion clinique et extrapolation des résultats, p.74

. Trente-cinq-patients, 5%) ont bénéficié d'une prise en charge chirurgicale Quatre (66,6%) des IOA natives ont bénéficié d'un lavage, 91%) ont été opérées, par simple lavage dans 15 cas (48.3%), ou par changement en un (n=11, 35.4%) ou deux (n=5, 16%) temps. 4. Description de l'antibiothérapie, p.31

. Dix-sept-patients, 5%) ont bénéficié d'un traitement par glycopeptides bien que la souche soit méti-S, du fait d'allergie ou d'effet secondaire aux pénicillines M pour deux cas, de la survenue d'une infection intercurrente dans un cas, d'une infection polymicrobienne dans trois cas

. La-téicoplanine-a-Été-prescrite, Pour les autres, le délai médian d'introduction de la téicoplanine était de 23 jours (IQR Les antibiotiques les plus utilisés avant la téicoplanine étaient les pénicillines M dans 10 cas (25%), les fluoroquinolones dans 10 cas (25%) et la vancomycine dans 9 cas (22.5%) La durée médiane du traitement par téicoplanine était de 45.5 jours (IQR, 29.2-78.7), pour une durée médiane de traitement antibiotique total de 124 jours (IQR, Le traitement par téicoplanine a été interrompu de façon programmée dans 19 cas (47.5%), et écourté chez 8 patients (20%) pour les raisons suivantes : 3 décès, 1 réaction inflammatoire, pp.6-535

M. Titécat, E. Senneville, F. Wallet, H. Dezèque, H. Migaud et al., Bacterial epidemiology of osteoarticular infections in a referent center: 10-year study, Orthopaedics & Traumatology: Surgery & Research, vol.99, issue.6, pp.653-661, 2013.
DOI : 10.1016/j.otsr.2013.02.011

A. Trampuz and W. Zimmerli, Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis, Current Infectious Disease Reports, vol.32, issue.5, pp.394-403, 2008.
DOI : 10.1007/s11908-008-0064-1

H. Autorité and D. Santé, Prothèse de hanche ou de genou : diagnostic et prise en charge de l'infection dans le mois suivant l'implantation

J. Martínez-pastor, E. Muñoz-mahamud, F. Vilchez, S. García-ramiro, G. Bori et al., Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis, Antimicrobial Agents and Chemotherapy, vol.53, issue.11, pp.4772-4779, 2009.
DOI : 10.1128/AAC.00188-09

G. Coiffier, J. Albert, C. Arvieux, and P. Guggenbuhl, Optimizing combination rifampin therapy for staphylococcal osteoarticular infections, Joint Bone Spine, vol.80, issue.1, 2013.
DOI : 10.1016/j.jbspin.2012.09.008

D. Stengel, K. Bauwens, J. Sehouli, A. Ekkernkamp, and F. Porzsolt, Systematic review and meta-analysis of antibiotic therapy for bone and joint infections, The Lancet Infectious Diseases, vol.1, issue.3, pp.175-88, 2001.
DOI : 10.1016/S1473-3099(01)00094-9

J. Marschall, M. Lane, S. Beekmann, P. Polgreen, and H. Babcock, Current management of prosthetic joint infections in adults: results of an Emerging Infections Network survey, International Journal of Antimicrobial Agents, vol.41, issue.3, pp.272-279, 2013.
DOI : 10.1016/j.ijantimicag.2012.10.023

C. For, M. Products-for-human, and . Use, Evaluation scientifique de Targocid et noms associés [Internet]. European Medicines Agency Available from, 2013.

A. Pichot, O. Mimoz, and W. Couet, Pharmacologie des antibiotiques en reanimation [Internet]. Société Française d'Anésthésie Réanimation Available from, 2013.

I. Odenholt, E. Löwdin, and O. Cars, In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium, Clinical Microbiology and Infection, vol.9, issue.9, 2003.
DOI : 10.1046/j.1469-0691.2003.00692.x

M. Cooper, Y. Jin, J. Ashby, J. Andrews, and R. Wise, In-vitro comparison of the postantibiotic effect of vancomycin and teicoplanin, Journal of Antimicrobial Chemotherapy, vol.26, issue.2, 1990.
DOI : 10.1093/jac/26.2.203

A. Wilson, Clinical Pharmacokinetics of Teicoplanin, Clinical Pharmacokinetics, vol.44, issue.3, 2000.
DOI : 10.2165/00003088-200039030-00001

A. Saleh-mghir, C. Crémieux, A. Bleton, R. Ismael, F. Manteau et al., Efficacy of Teicoplanin and Autoradiographic Diffusion Pattern of [14C]Teicoplanin in Experimental Staphylococcus aureus Infection of Joint Prostheses, Antimicrob Agents Chemother, vol.42, issue.11, pp.2830-2835, 1998.

A. Brink, G. Richards, E. Lautenbach, N. Rapeport, V. Schillack et al., Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis, International Journal of Antimicrobial Agents, vol.45, issue.6, pp.647-51
DOI : 10.1016/j.ijantimicag.2015.01.015

T. Enokiya, Y. Muraki, T. Iwamoto, and M. Okuda, Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin, International Journal of Antimicrobial Agents, vol.46, issue.2, 2015.
DOI : 10.1016/j.ijantimicag.2015.03.010

Y. Peng, X. Ye, Y. Li, T. Bu, X. Chen et al., Teicoplanin as an Effective Alternative to Vancomycin for Treatment of MRSA Infection in Chinese Population: A Meta-analysis of Randomized Controlled Trials, PLoS ONE, vol.53, issue.11, p.79782, 2013.
DOI : 10.1371/journal.pone.0079782.s001

F. Trueba, E. Garrabe, R. Hadef, R. Fabre, J. Cavallo et al., High Prevalence of Teicoplanin Resistance among Staphylococcus epidermidis Strains in a 5-Year Retrospective Study, Journal of Clinical Microbiology, vol.44, issue.5, pp.1922-1925, 2006.
DOI : 10.1128/JCM.44.5.1922-1923.2006

J. Liñares, The VISA/GISA problem: therapeutic implications, Clinical Microbiology and Infection, vol.7, issue.4, pp.8-15, 2001.
DOI : 10.1046/j.1469-0691.2001.00054.x

A. Wilson, Comparative safety of teicoplanin and vancomycin, International Journal of Antimicrobial Agents, vol.10, issue.2, pp.143-52, 1998.
DOI : 10.1016/S0924-8579(98)00025-9

Y. Hung, N. Lee, C. Chang, H. Lee, C. Wu et al., Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: A retrospective chart review, Clinical Therapeutics, vol.31, issue.9, pp.1977-86, 2009.
DOI : 10.1016/j.clinthera.2009.09.010

F. Pea, P. Viale, F. Pavan, M. Tavio, D. Poz et al., The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin, International Journal of Antimicrobial Agents, vol.27, issue.4, pp.344-50, 2006.
DOI : 10.1016/j.ijantimicag.2005.11.012

J. Roberts, V. Stove, D. Waele, J. Sipinkoski, B. Mcwhinney et al., Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study, International Journal of Antimicrobial Agents, vol.43, issue.5, pp.423-453, 2014.
DOI : 10.1016/j.ijantimicag.2014.01.023

A. Macgowan, L. White, D. Reeves, and I. Harding, Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome, Journal of Infection and Chemotherapy, vol.2, issue.4, pp.197-208, 1996.
DOI : 10.1007/BF02355116

I. Harding, A. Macgowan, L. White, E. Darley, and V. Reed, Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, Journal of Antimicrobial Chemotherapy, vol.45, issue.6, pp.835-876, 2000.
DOI : 10.1093/jac/45.6.835

F. Pea, L. Brollo, P. Viale, F. Pavan, and M. Furlanut, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, Journal of Antimicrobial Chemotherapy, vol.51, issue.4, pp.971-976, 2003.
DOI : 10.1093/jac/dkg147

R. Greenberg, Treatment of bone, joint, and vascular-access-associated grampositive bacterial infections with teicoplanin, Antimicrob Agents Chemother, 1990.

A. Brink, G. Richards, R. Cummins, and J. Lambson, Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis, International Journal of Antimicrobial Agents, vol.32, issue.5, pp.455-463, 2008.
DOI : 10.1016/j.ijantimicag.2008.05.012

P. Matthews, A. Taylor, I. Byren, and B. Atkins, Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?, Journal of Infection, vol.55, issue.5, pp.408-421, 2007.
DOI : 10.1016/j.jinf.2007.07.012

M. Sato, K. Chida, T. Suda, H. Muramatsu, Y. Suzuki et al., Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level, Journal of Infection and Chemotherapy, vol.12, issue.4, pp.185-194, 2006.
DOI : 10.1007/s10156-006-0446-Y

T. Ueda, Y. Takesue, K. Nakajima, K. Ichki, Y. Wada et al., Evaluation of teicoplanin dosing designs to achieve a new target trough concentration, Journal of Infection and Chemotherapy, vol.18, issue.3, pp.296-302
DOI : 10.1007/s10156-011-0325-z

K. Matsumoto, N. Kanazawa, K. Ikawa, T. Fukamizu, A. Shigemi et al., Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections, Journal of Infection and Chemotherapy, vol.16, issue.3, pp.193-202, 2010.
DOI : 10.1007/s10156-010-0038-8

J. Wang, H. Liao, W. Lin, F. Chang, and S. , Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrugresistant gram-positive infections, Basic Clin Pharmacol Toxicol, 2012.

T. Yamada, T. Nonaka, T. Yano, T. Kubota, N. Egashira et al., Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation, International Journal of Antimicrobial Agents, vol.40, issue.4, pp.344-352, 2012.
DOI : 10.1016/j.ijantimicag.2012.05.025

T. Wang, N. Li, S. Hu, J. Xie, J. Lei et al., Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections, Int. Journal of Clinical Pharmacology and Therapeutics, vol.53, issue.05, pp.356-62
DOI : 10.5414/CP202247

C. Byrne, S. Egan, J. Fennell, O. Byrne, P. Enright et al., Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity, International Journal of Antimicrobial Agents, vol.46, issue.4, pp.406-418, 2015.
DOI : 10.1016/j.ijantimicag.2015.05.019

W. Zhao, D. Zhang, T. Storme, A. Baruchel, X. Declèves et al., Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease, British Journal of Clinical Pharmacology, vol.7, issue.5, pp.1197-207, 2015.
DOI : 10.1111/bcp.12710

T. Niwa, Y. Imanishi, T. Ohmori, K. Matsuura, N. Murakami et al., Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics, International Journal of Antimicrobial Agents, vol.35, issue.5, pp.507-517, 2010.
DOI : 10.1016/j.ijantimicag.2009.12.018

N. Kanazawa, K. Matsumoto, K. Ikawa, T. Fukamizu, A. Shigemi et al., An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication, Journal of Infection and Chemotherapy, vol.17, issue.2, pp.297-300, 2011.
DOI : 10.1007/s10156-010-0105-1

P. Matthews, A. Chue, D. Wyllie, A. Barnett, T. Isinkaye et al., Increased teicoplanin doses are associated with improved serum levels but not drug toxicity, Journal of Infection, vol.68, issue.1, pp.43-52
DOI : 10.1016/j.jinf.2013.08.018

M. Yoshida, S. Matzno, H. Namba, M. Nishikata, and K. Matsuyama, Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK), Journal of Infection and Chemotherapy, vol.12, issue.3, 2006.
DOI : 10.1007/s10156-006-0437-Z

A. Wilson, R. Grüneberg, and H. Neu, Dosage recommendations for teicoplanin, Journal of Antimicrobial Chemotherapy, vol.32, issue.6, pp.792-798, 1993.
DOI : 10.1093/jac/32.6.792

A. Nakamura, O. Takasu, Y. Sakai, T. Sakamoto, N. Yamashita et al., Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections, Journal of Infection and Chemotherapy, vol.21, issue.6, pp.449-55
DOI : 10.1016/j.jiac.2015.02.002

R. Dugas, Conseils pratiques. La voie sous-cutanée. Une alternative utile en soins palliatifs. Can Fam Physician, Feb, vol.47, pp.266-273, 2001.

H. Pharmacie-des, Administration de médicaments par voie sous cutanée [Internet] Available from: http://pharmacie.hug-ge, 2015.

S. Lipschitz, A. Campbell, M. Roberts, S. Wanwimolruk, E. Mcqueen et al., Subcutaneous Fluid Administration in Elderly Subjects: Validation of an Under-Used Technique, Journal of the American Geriatrics Society, vol.31, issue.6, pp.6-9, 1991.
DOI : 10.1111/j.1532-5415.1991.tb05898.x

H. Shah, W. Bosch, K. Thompson, and W. Hellinger, Intravascular Catheter-Related Bloodstream Infection. The Neurohospitalist, pp.144-51, 2013.

C. Chernecky, D. Macklin, and P. Blackburn, Catheter-Related Bloodstream Infections (CR-BSI) in Geriatric Patients in Intensive Care Units, Critical Care Nursing Quarterly, vol.38, issue.3, p.2015
DOI : 10.1097/CNQ.0000000000000076

V. Dardaine-giraud, M. Lamandé, and T. Constans, Hypodermoclysis: benefits and indications in geriatrics]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.643-50, 2005.

A. Robelet, T. Caruba, A. Corvol, D. Bégué, M. Gisselbrecht et al., Antibiotiques par voie sous-cutan??e chez la personne ??g??e, Presse Médicale, 2009.
DOI : 10.1016/j.lpm.2008.07.018

E. Forestier, M. Paccalin, C. Roubaud-baudron, T. Fraisse, G. Gavazzi et al., Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks, Clinical Microbiology and Infection, vol.21, issue.4, 2015.
DOI : 10.1016/j.cmi.2014.11.017

. Forestier, Etude prospective de la tolérance des antibiotiques administrés par voie sous-cutanée [Internet] Available from: https, 2015.

V. Gassler, J. Stirnemman, V. Prendki, and A. Huttner, Antibiothérapie par voie sous-cutanée chez le patient âgé, Rev Médicale Suisse, issue.446, pp.1924-1933, 2014.

F. Melin-coviaux, L. Hary, A. Hurtel, M. Andrejak, and Y. Grumbach, Etude pharmacoclinique comparative de la ceftriaxone par voie sous-cutanée et intraveineuse chez la personne âgée, Rev Gériatrie, vol.25, issue.5, pp.337-384, 2000.

D. Gauthier, S. Schambach, J. Crouzet, S. Sirvain, and T. Fraisse, Subcutaneous and intravenous ceftriaxone administration in patients more than 75??years of age, M??decine et Maladies Infectieuses, vol.44, issue.6
DOI : 10.1016/j.medmal.2014.03.007

P. Walker, M. Neuhauser, V. Tam, J. Willey, J. Palmer et al., Subcutaneous Administration of Cefepime, Journal of Pain and Symptom Management, vol.30, issue.2, 2005.
DOI : 10.1016/j.jpainsymman.2005.03.007

E. Forestier, S. Gros, D. Peynaud, M. Levast, D. Boisseau et al., Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea, Médecine Mal Infect, 2012.

N. Champoux, D. Souich, P. Ravaoarinoro, M. Phaneuf, D. Latour et al., Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers, British Journal of Clinical Pharmacology, vol.42, issue.3, pp.325-356, 1996.
DOI : 10.1046/j.1365-2125.1996.03967.x

C. Fonzo-christe, C. Vukasovic, A. Wasilewski-rasca, and P. Bonnabry, Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review, Palliative Medicine, vol.12, issue.2, pp.208-227, 2005.
DOI : 10.1191/0269216304pm1006oa

W. Craig and . Pharmacokinetic, pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis Off Publ Infect Dis Soc Am, pp.1-10, 1998.

A. Barbot, N. Venisse, F. Rayeh, S. Bouquet, B. Debaene et al., Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors, Intensive Care Medicine, vol.29, issue.9, pp.1528-1562, 2003.
DOI : 10.1007/s00134-003-1859-z

E. Carpentier, B. Roméo, E. Samad, Y. Geslin-lichtenberger, L. Maingourd et al., Subcutaneous teicoplanin for children with infectious endocarditis]. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, pp.775-783, 2013.

T. Peel, A. Cheng, P. Choong, and K. Buising, Early onset prosthetic hip and knee joint infection: treatment and outcomes in Victoria, Australia, Journal of Hospital Infection, vol.82, issue.4, 2012.
DOI : 10.1016/j.jhin.2012.09.005

S. Ferchichi and A. V. , Appropriate drug prescribing in the elderly]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.582-90, 2004.

C. Lafuente-lafuente, E. Baudry, E. Paillaud, and F. Piette, Clinical pharmacology and aging]. Presse Médicale Paris Fr 1983, Feb, vol.42, issue.2, pp.171-80, 2013.

F. Buntinx, L. Niclaes, C. Suetens, B. Jans, R. Mertens et al., Evaluation of Charlson's comorbidity index in elderly living in nursing homes, Journal of Clinical Epidemiology, vol.55, issue.11, 2002.
DOI : 10.1016/S0895-4356(02)00485-7

M. Uhart, B. Leroy, A. Michaud, P. Maire, and L. Bourguignon, Inter-individual and intraindividual pharmacokinetic variability during teicoplanin therapy in geriatric patients

L. Bourguignon, S. Goutelle, P. Bouniot, A. Guillermet, J. Saint-martin et al., Pharmacocinétique de la teicoplanine chez le sujet Agé : construction d'un modèle pour le suivi thérapeutique, J Pharm Clin, vol.27, issue.3, pp.189-94, 2008.

A. Tice, S. Rehm, J. Dalovisio, J. Bradley, L. Martinelli et al., Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis Off Publ Infect Dis Soc Am, pp.1651-72, 2004.

S. Esposito, S. Leone, S. Noviello, F. Ianniello, M. Fiore et al., Outpatient Parenteral Antibiotic Therapy for Bone and Joint Infections: An Italian Multicenter Study, Journal of Chemotherapy, vol.15, issue.117, pp.417-439, 2007.
DOI : 10.2165/00019053-200321060-00004

C. Yong, D. Fisher, G. Sklar, and S. Li, A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective, International Journal of Antimicrobial Agents, vol.33, issue.1, 2009.
DOI : 10.1016/j.ijantimicag.2008.07.016

P. Matthews, C. Conlon, A. Berendt, K. J. Jefferies, L. Atkins et al., Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years, Journal of Antimicrobial Chemotherapy, vol.60, issue.2, pp.356-62, 2007.
DOI : 10.1093/jac/dkm210

R. Seaton and D. Barr, Outpatient parenteral antibiotic therapy: Principles and practice, European Journal of Internal Medicine, vol.24, issue.7
DOI : 10.1016/j.ejim.2013.03.014

R. Seaton and D. Nathwani, Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: survey of infection specialists' experience and views, Clinical Microbiology and Infection, vol.6, issue.7, pp.387-90, 2000.
DOI : 10.1046/j.1469-0691.2000.00112.x

A. Goodfellow, A. Wai, L. Frighetto, C. Marra, B. Ferreira et al., Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program, Annals of Pharmacotherapy, vol.12, issue.12, pp.1851-1856, 2002.
DOI : 10.1345/aph.1C153

M. Mackenzie, R. N. Nathwani, and D. , Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: A review of the last decade, International Journal of Antimicrobial Agents, vol.43, issue.1, pp.7-16, 2014.
DOI : 10.1016/j.ijantimicag.2013.09.006

C. Ruh, G. Parameswaran, A. Wojciechowski, and K. Mergenhagen, Outcomes and Pharmacoeconomic Analysis of a Home Intravenous Antibiotic Infusion Program in Veterans, Clinical Therapeutics, vol.37, issue.11, pp.2527-2562, 2015.
DOI : 10.1016/j.clinthera.2015.09.009

A. Tice, The Use of Outpatient Parenteral Antimicrobial Therapy in the Management of Osteomyelitis: Data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries, Chemotherapy, vol.47, issue.Suppl. 1, pp.5-16, 2001.
DOI : 10.1159/000048563

C. Mackintosh, H. White, and R. Seaton, Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service, Journal of Antimicrobial Chemotherapy, vol.66, issue.2, pp.408-423, 2011.
DOI : 10.1093/jac/dkq445

E. Lamont, R. Seaton, M. Macpherson, L. Semple, E. Bell et al., Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme, Journal of Antimicrobial Chemotherapy, vol.64, issue.1, pp.181-188, 2009.
DOI : 10.1093/jac/dkp147

R. Seaton, E. Sharp, V. Bezlyak, and C. Weir, Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections, International Journal of Antimicrobial Agents, vol.38, issue.3, pp.243-251, 2011.
DOI : 10.1016/j.ijantimicag.2011.05.008

URL : https://hal.archives-ouvertes.fr/hal-00722868

C. Duncan, D. Barr, A. Ho, E. Sharp, L. Semple et al., Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis, Journal of Antimicrobial Chemotherapy, vol.68, issue.7, pp.1650-1654
DOI : 10.1093/jac/dkt046

W. Graninger, C. Wenisch, E. Wiesinger, M. Menschik, J. Karimi et al., Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis, European Journal of Clinical Microbiology & Infectious Diseases, vol.567, issue.Supplement 2, pp.643-650, 1995.
DOI : 10.1007/BF01690746

P. Dang, C. Gouin, F. Touchais, S. Richard, C. Potel et al., Le co??t comparatif du traitement par vancomycine versus teicoplanine dans l'infection ost??oarticulaire ?? staphylocoques r??sistants ?? la m??ticilline, Pathologie Biologie, vol.49, issue.7, pp.587-96, 2001.
DOI : 10.1016/S0369-8114(01)00203-6

D. Nathwani, G. Barlow, K. Ajdukiewicz, K. Gray, J. Morrison et al., Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy, Journal of Antimicrobial Chemotherapy, vol.51, issue.2, pp.391-397, 2003.
DOI : 10.1093/jac/dkg061

M. Titécat, E. Senneville, F. Wallet, H. Dezèque, H. Migaud et al., Microbiologic Profile of Staphylococci Isolated from Osteoarticular Infections: Evolution over Ten Years, Surgical Infections, vol.16, issue.1, pp.77-83, 2015.
DOI : 10.1089/sur.2013.258

A. Barbot, N. Venisse, F. Rayeh, S. Bouquet, B. Debaene et al., Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors, Intensive Care Medicine, vol.29, issue.9, pp.1528-1562, 2003.
DOI : 10.1007/s00134-003-1859-z

M. Charlson, P. Pompei, K. Ales, and C. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, Journal of Chronic Diseases, vol.40, issue.5, pp.373-83, 1987.
DOI : 10.1016/0021-9681(87)90171-8

M. Dowsey and P. Choong, Obesity is a Major Risk Factor for Prosthetic Infection after Primary Hip Arthroplasty, Clinical Orthopaedics and Related Research, vol.78, issue.suppl 2, pp.153-161, 2008.
DOI : 10.1007/s11999-007-0016-3

F. Valour, J. Karsenty, A. Bouaziz, F. Ader, M. Tod et al., Antimicrobial-Related Severe Adverse Events during Treatment of Bone and Joint Infection Due to Methicillin-Susceptible Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.58, issue.2, pp.746-55, 2014.
DOI : 10.1128/AAC.02032-13

F. Capelle and J. Gaudias, Bon usage de la Teicoplanine : analyse retrospective d'une pratique clinique dans la prise en charge des infections ostéoarticulaires

O. Peeters, T. Ferry, A. Boibieux, M. Vallat, A. Bouaziz et al., Sébastien Lustig, Christian Chidiac, et Florent Valour, pour le Lyon BJI study group. Efficacy and tolerance of teicoplanin in Staphylococcus aureus bone and joint infection -Thèse d'exercice

C. Pensotti, F. Nacinovich, G. Vidiella, E. Carbone, M. Marin et al., Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients], Medicina (Mex), vol.62, issue.2, pp.40-47, 2002.

C. Watts, E. Wagner, M. Houdek, D. Osmon, A. Hanssen et al., Morbid Obesity: A Significant Risk Factor for Failure of Two-Stage Revision Total Knee Arthroplasty for Infection, The Journal of Bone and Joint Surgery-American Volume, vol.96, issue.18, p.154, 2014.
DOI : 10.2106/JBJS.M.01289

W. Weinberg, P. I. Rafailidis, and &. M. Falagas, Safety and Efficacy of Teicoplanin for Bone and Joint Infections: Results of a Community-Based Trial, Southern Medical Journal, vol.86, issue.8, 1993.
DOI : 10.1097/00007611-199308000-00009

J. Lefrock and A. Ristuccia, Teicoplanin in the treatment of bone and joint infections: An open study, Journal of Infection and Chemotherapy, vol.5, issue.1, pp.32-41, 1999.
DOI : 10.1007/s101560050005

K. Z. Vardakas, &. I. Kontopidis, &. I. Gkegkes, and &. , Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review, European Journal of Clinical Microbiology & Infectious Diseases, vol.46, issue.6
DOI : 10.1007/s10096-012-1807-3

J. Lee, C. Kang, J. Lee, M. Joung, S. Moon et al., Risk factors for treatment failure in patients with prosthetic joint infections, Journal of Hospital Infection, vol.75, issue.4, 2010.
DOI : 10.1016/j.jhin.2010.03.012

C. Marculescu, E. Berbari, A. Hanssen, J. Steckelberg, S. Harmsen et al., Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis Off Publ Infect Dis Soc Am, Feb, vol.1542, issue.4, pp.471-479, 2006.

K. Park, Y. Chong, S. Kim, S. Lee, S. Choi et al., Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus, Journal of Infection, vol.67, issue.6, pp.556-64, 2013.
DOI : 10.1016/j.jinf.2013.07.026

D. Kilgus, D. Howe, and A. Strang, Results of Periprosthetic Hip and Knee Infections Caused by Resistant Bacteria, Clinical Orthopaedics and Related Research, vol.404, issue.404, pp.116-140, 2002.
DOI : 10.1097/00003086-200211000-00021

C. Salgado, S. Dash, J. Cantey, and C. Marculescu, Higher Risk of Failure of Methicillin-resistant Staphylococcus aureus Prosthetic Joint Infections, Clinical Orthopaedics and Related Research, vol.PAP, pp.48-53, 2007.
DOI : 10.1097/BLO.0b013e3181123d4e

A. Tice, P. Hoaglund, and D. Shoultz, Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy, The American Journal of Medicine, vol.114, issue.9, pp.723-731, 2003.
DOI : 10.1016/S0002-9343(03)00231-6

T. Nakamura and H. Takahashi, Drug Sensitivity and Teicoplanin Resistance of Coagulase-negative Staphylococcus Isolated from Blood Culture, Journal of the Japanese Association for Infectious Diseases, vol.78, issue.1, pp.46-53, 2004.
DOI : 10.11150/kansenshogakuzasshi1970.78.46

K. Chen, H. Chang, P. Hsu, C. Yang, J. Chia et al., Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin- 110

S. Van-hal, T. Lodise, and D. Paterson, The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis, Clinical Infectious Diseases, vol.54, issue.6, 2012.
DOI : 10.1093/cid/cir935

E. Samad, Y. Brunschweiler, B. Routier, and S. , Tolérance locale de la téicoplanine après administration prolongée en sous-cutanée chez 27 patients traités pour des infections ostéoarticulaires, p.2015

J. Thiolet, S. Vaux, M. Lamy, A. Gautier, A. Barret et al., Coignard pour le groupe

T. Ferry, A. Sénéchal, M. Gagnieu, A. Boibieux, F. Laurent et al., Prolonged subcutaneous high dose (1??g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection, Journal of Infection, vol.65, issue.6, pp.579-82, 2012.
DOI : 10.1016/j.jinf.2012.09.004

URL : https://hal.archives-ouvertes.fr/inserm-00734708

D. Penso, J. Delfraissy, P. Van, T. Dormont, and J. , Skin necrosis following administration of subcutaneous gentamicin]. Presse Médicale Paris Fr 1983, Jun, vol.1613, issue.25, pp.1575-1581, 1984.

F. Bricaire, J. Castaing, J. Pocidalo, and J. Vilde, Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration], Pathol Biol, vol.36, issue.5 2, pp.702-707, 1988.

J. Allen, K. Adams, F. Thompson, L. Cullen, and G. Barlow, Long-term, once-weekly outpatient teicoplanin use for suppression of chronic prosthetic joint infection, International Journal of Antimicrobial Agents, vol.41, issue.2, pp.200-201, 2013.
DOI : 10.1016/j.ijantimicag.2012.10.006

L. Grammatico-guillon, guillon@univ-tours.fr)1,2,3, Sabine Baron3, Sharmeen Gettner3, 2008.

J. Kuti, C. Kiffer, C. Mendes, and D. Nicolau, Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil, Clinical Microbiology and Infection, vol.14, issue.2, pp.116-139, 2008.
DOI : 10.1111/j.1469-0691.2007.01885.x